Abstract: A method of generating training data for training a Machine Learning based Task Contention Model, ML based TCM, to predict time delays resulting from contention between tasks running in parallel on a multi-processor system is provided herein. The method includes: executing a plurality of microbenchmarks, ?Benchmarks Bj, on the multi-processor system in isolation and measuring a number of resultant Performance Monitoring Counters, PMCs, over time to extract ideal characteristic footprints of each ?Benchmark when operating in isolation; performing a feature correlation analysis on the PMCs resulting from the plurality of ?Benchmarks to determine the degree of correlation between each resultant PMCs and the executed plurality of ?Benchmarks; selecting a number of PMCs based upon their degree of correlation between the plurality of ?Benchmarks to form a reduced PMC array.

Abstract: A computer-implemented method schedules a plurality of tasks for execution by a processor system. A first execution model for the plurality of tasks is accessed. Data is generated that identifies which tasks in the execution model are not direct-feedthrough tasks. The data is used to determine an order for executing the tasks at least partly in dependence on whether or not each task is a direct-feedthrough task.

Abstract: A computer-implemented method of producing a trained Machine Learning based Task Contention Model to predict time delays resulting from contention between tasks running in parallel on a multi-processor system is provided herein.

Abstract: A computer-implemented method schedules a plurality of tasks for execution by a multi-processor system. A first schedule is generated that assigns each task of the plurality of tasks a time window and a processor of the multi-processor system. A contention model for the multi-processor system is queried to determine a contention delay for the assignment of tasks to processors according to the first schedule. The contention delay determined from the contention model is used to generate, from the first schedule, a revised schedule that assigns each task a time window and a processor of the multi-processor system, wherein the revised schedule is determined in dependence on the determined contention delay.

Abstract: An inhibitor of IL-38 is useful for treating and/or preventing cancer in a subject. A pharmaceutical composition can include an inhibitor of IL-38. A method for treating and/or preventing cancer is carried out by administering an inhibitor of IL-38 in a therapeutically effective amount. Another method is useful for identifying an inhibitor of IL-38.

Abstract: A caulking tool configured to be frictionally attached to a user's finger during use. The caulking tool in one example having; a convex caulk spreader comprising a pliable spreader surface configured to spread caulk smoothly between a first wall surface and a second wall surface to which the caulk is adhered. In one example junction between a first wall surface and a second wall surface will be in a corner junction between the two wall surfaces. In one example the caulking tool comprises a finger tube fixed to the caulk spreader. The finger tube may be cast with the spreader surface and thus forms a monolithic, single component without seams therebetween. The finger tube in one example having an inner surface configured to frictionally engage the outer surface of a user's finger. In one example the inner surface of the finger tube is tapered from a first longitudinal end to a second longitudinal end.

Abstract: The present invention pertains to an N-terminally truncated interleukin (IL)-38 protein, or functional variants thereof, as well as to nucleic acids and vectors encoding the truncated IL-38 peptide and recombinant cells comprising these nucleic acids or vectors. The invention shows that IL-38 is N-terminally processed and that the truncated version of the cytokine acts as an antagonist of immune activation in macrophages. This indicates a use of the truncated cytokine in the treatment and prevention of autoimmune disorders. The invention further provides pharmaceutical compositions comprising the truncated IL-38 protein, and method for screening modulators of the function of truncated IL-38.

Abstract: An inhibitor of IL-38 is useful for treating and/or preventing cancer in a subject. A pharmaceutical composition can include an inhibitor of IL-38. A method for treating and/or preventing cancer is carried out by administering an inhibitor of IL-38 in a therapeutically effective amount. Another method is useful for identifying an inhibitor of IL-38.

Abstract: The present invention pertains to an N-terminally truncated interleukin (IL)-38 protein, or functional variants thereof, as well as to nucleic acids and vectors encoding the truncated IL-38 peptide and recombinant cells comprising these nucleic acids or vectors. The invention shows that IL-38 is N-terminally processed and that the truncated version of the cytokine acts as an antagonist of immune activation in macrophages. This indicates a use of the truncated cytokine in the treatment and prevention of autoimmune disorders. The invention further provides pharmaceutical compositions comprising the truncated IL-38 protein, and method for screening modulators of the function of truncated IL-38.

Abstract: An injection needle assembly (50) for an injection device, having a) a needle cannula (3) attached to a needle hub (4) and defining a pointed tip at a free end (3a, 3b), and b) a needle cover (10, 10a, 10b) forming an axially extending elongated flexible enclosure accommodating the needle cannula (3). The needle cover (10, 10a, 10b) is configured to axially collapse and become penetrated by the needle cannula (3) when a penetration force is applied to the needle cover. The needle cover (10, 10a, 10b) defines a shaft section (11a) and a bulb section (11b). The shaft section (11a) encircles the needle cannula (3) and extends axially from the needle hub (4) to the bulb section (11b). The shaft section (11a) comprises a collapsible wall area (15) having wall thickness t1 less than a predefined wall thickness t1,lim to provide radial deformability for abutting contact with the needle cannula (3).

Abstract: An injection needle assembly (50) for an injection device, comprising: a) a needle cannula (3) attached to a needle hub (4) and defining a pointed tip at a free end (3a, 3b), and b) a needle cover (10, 10a, 10b) forming an axially extending elongated flexible enclosure accommodating the needle cannula (3). The needle cover (10, 10a, 10b) is configured to axially collapse and become penetrated by the needle cannula (3) when a penetration force is applied to the needle cover. The needle cover (10, 10a, 10b) defines a shaft section (11a) and a bulb section (11b). The shaft section (11a) encircles the needle cannula (3) and extends axially from the needle hub (4) to the bulb section (11b). The shaft section (11a) comprises a collapsible wall area (15) having wall thickness t1 less than a predefined wall thickness t1,lim to provide radial deformability for abutting contact with the needle cannula (3).

Abstract: An injection needle assembly (50) for an injection device, comprising: a) a needle cannula (3) attached to a needle hub (4) and defining a pointed tip at a free end (3a, 3b), and b) a needle cover (10, 10a, 10b) forming an axially extending elongated flexible enclosure accommodating the needle cannula (3). The needle cover (10, 10a, 10b) is configured to axially collapse and become penetrated by the needle cannula (3) when a penetration force is applied to the needle cover. The needle cover (10, 10a, 10b) defines a shaft section (11a) and a bulb section (11b). The shaft section (11a) encircles the needle cannula (3) and extends axially from the needle hub (4) to the bulb section (11b). The shaft section (11a) comprises wall areas of minimum wall thickness t1 whereas the bulb section (11b) comprises wall areas (17a, 17b) having a wall thickness t2 larger than said minimum wall thickness t1.

Abstract: The present invention pertains to an N-terminally truncated interleukin (IL)-38 protein, or functional variants thereof, as well as to nucleic acids and vectors encoding the truncated IL-38 peptide and recombinant cells comprising these nucleic acids or vectors. The invention shows that IL-38 is N-terminally processed and that the truncated version of the cytokine acts as an antagonist of immune activation in macrophages. This indicates a use of the truncated cytokine in the treatment and prevention of autoimmune disorders. The invention further provides pharmaceutical compositions comprising the truncated IL-38 protein, and method for screening modulators of the function of truncated IL-38.

Abstract: A paint tray with disposable liner system generally comprises two components, a paint tray base, and a liner holding frame which cooperatively engages with the paint tray base to securely hold a paint tray liner therebetween so as to position the paint tray liner overtop of the interior surface of the paint tray base. The paint tray base has a bumper extending around the periphery of the paint tray base from the exterior surface of its walls. The liner holding frame is sized to slidingly fit onto the paint tray base and engage the bumper, wherein engagement of the liner holding frame with the bumper securely fixes a paint tray liner in place therebetween. A cover can optionally be included in the system that includes a cover holding frame sized to fit on top of the paint tray base above the liner holding frame, wherein the cover holding frame comprises a channel to receive a top end of a corresponding wall of the paint tray base to securely fix the paint tray cover in place therebetween.

Abstract: A paint tray with disposable liner system generally comprises two components, a paint tray base, and a liner holding frame which cooperatively engages with the paint tray base to securely hold a paint tray liner therebetween so as to position the paint tray liner overtop of the interior surface of the paint tray base. The paint tray base has a bumper extending around the periphery of the paint tray base from the exterior surface of its walls. The liner holding frame is sized to slidingly fit onto the paint tray base and engage the bumper, wherein engagement of the liner holding frame with the bumper securely fixes a paint tray liner in place therebetween. A cover can optionally be included in the system that includes a cover holding frame sized to fit on top of the paint tray base above the liner holding frame, wherein the cover holding frame comprises a channel to receive a top end of a corresponding wall of the paint tray base to securely fix the paint tray cover in place therebetween.

Abstract: A needle magazine (10, 110) for storing a plurality of pen needle assemblies in combination with a plurality of pen needle units is disclosed. The magazines each comprise a first part (11, 111) and a second part (12, 112), each holding a number of pen needle assemblies. The first part (11, 111) and the second part (12, 112) are hinged together by a hinge mechanism (13, 113) such that the pen needle magazine (10, 110) can be folded to be easily carried by a user. The needle magazine (10, 110) also comprises an irreversible locking mechanism (30, 31, 130) such that the needle magazine (10, 110) can be used as a waste bin when discarding the used pen needle assemblies.

Abstract: A needle magazine (10, 110) for storing a plurality of pen needle assemblies in combination with a plurality of pen needle units is disclosed. The magazines each comprise a first part (11, 111) and a second part (12, 112), each holding a number of pen needle assemblies. The first part (11, 111) and the second part (12, 112) are hinged together by a hinge mechanism (13, 113) such that the pen needle magazine (10, 110) can be folded to be easily carried by a user. The needle magazine (10, 110) also comprises an irreversible locking mechanism (30, 31, 130) such that the needle magazine (10, 110) can be used as a waste bin when discarding the used pen needle assemblies.